APA (7th ed.) Citation

Stares, M., Doyle, E., Chapple, S., Raynes, G., MacDonald, J., Barrie, C., . . . Philips, I. (2024). Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab. Lung Cancer (01695002), 189, N.PAG. https://doi.org/10.1016/j.lungcan.2024.107497

Chicago Style (17th ed.) Citation

Stares, Mark, Emma Doyle, Sally Chapple, George Raynes, James MacDonald, Colin Barrie, Barry Laird, Melanie MacKean, and Iain Philips. "Prognostic Value of the Scottish Inflammatory Prognostic Score in Patients with NSCLC Expressing PD-L1 ≥ 50 % Progressing on First-line Pembrolizumab." Lung Cancer (01695002) 189 (2024): N.PAG. https://doi.org/10.1016/j.lungcan.2024.107497.

MLA (9th ed.) Citation

Stares, Mark, et al. "Prognostic Value of the Scottish Inflammatory Prognostic Score in Patients with NSCLC Expressing PD-L1 ≥ 50 % Progressing on First-line Pembrolizumab." Lung Cancer (01695002), vol. 189, 2024, p. N.PAG, https://doi.org/10.1016/j.lungcan.2024.107497.